[人胰腺癌相关抗原（SPan-1抗原）在肝胆胰疾病中的临床研究]

[Clinical study of human pancreatic cancer-associated antigen (SPan-1 antigen) in hepatobiliary and pancreatic diseases].

作者信息

Nakata B, Chung Y S, Yokomatsu H, Tanaka H, Sawada T, Nishiwaki H, Satake K, Umeyama K, Seki S

机构信息

First Department of Surgery, Osaka City University Medical School.

出版信息

Nihon Shokakibyo Gakkai Zasshi. 1990 Apr;87(4):1050-5.

PMID:2376901

Abstract

We studied clinical significance of serum SPan-1 antigen, which is human pancreatic cancer associated antigen, in hepatobiliary and pancreatic diseases employing newly developed kit. The sensitivity of serum SPan-1 antigen levels for pancreatic cancer, gallbladder carcinoma, hepatocellular carcinoma, bile duct cancer were 90.9%, 77.8%, 60.7%, 60.0% respectively. No correlation was found between serum SPan-1 antigen levels and total bilirubin levels. SPan-1 positivity in patients with hepatic disease including hepatocellular carcinoma was rather high, but there were few cases more than 100 U/ml. The mechanism of the elevated level was supposed to be release of the antigen from bile-duct epithelium, and this must be taken into consideration at diagnosis referred to serum SPan-1 antigen level.

摘要

我们使用新开发的试剂盒，研究了血清SPan - 1抗原（一种人胰腺癌相关抗原）在肝胆胰疾病中的临床意义。血清SPan - 1抗原水平对胰腺癌、胆囊癌、肝细胞癌、胆管癌的敏感性分别为90.9%、77.8%、60.7%、60.0%。未发现血清SPan - 1抗原水平与总胆红素水平之间存在相关性。包括肝细胞癌在内的肝病患者中SPan - 1阳性率相当高，但超过100 U/ml的病例很少。抗原水平升高的机制被认为是抗原从胆管上皮释放，在参考血清SPan - 1抗原水平进行诊断时必须考虑到这一点。